Education
About Us
Working with TipRanks
Follow Us
MEDI - ETF AI Analysis
Top Page
Harbor Health Care ETF (MEDI)
Rating:61Neutral
Price Target:―
Positive Factors
Recent Performance Momentum
The ETF has shown steady gains over the past month and quarter, indicating positive recent momentum in its strategy.
Strong Health Care Leaders in Top Holdings
Several major positions like UnitedHealth, Masimo, Vaxcyte, Revolution Medicines, Natera, and Danaher have delivered strong year-to-date performance, helping support the fund’s returns.
Focused Exposure to U.S. Health Care
The fund’s heavy allocation to U.S. health care companies gives investors targeted access to a key defensive sector within a familiar market.
Negative Factors
High Concentration in a Single Sector
With almost all assets in health care, the ETF is heavily exposed to sector-specific risks such as regulatory changes and reimbursement pressures.
Dependence on a Few Large Positions
A small number of holdings, especially Eli Lilly and Ascendis Pharma, make up a large share of the portfolio, increasing the impact if these stocks struggle.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can eat into long-term returns compared with lower-cost alternatives.
MEDI vs. SPDR S&P 500 ETF (SPY)
AUM26.01M
RegionGlobal
Expense Ratio0.80%
Beta0.70
IssuerHarbor
Inception DateNov 17, 2022
Dividend Yield0.24%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,348
30 Day Avg. Volume8,352
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.69Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering35
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDI Summary
Harbor Health Care ETF (MEDI) is a fund that focuses on the U.S. health care sector rather than tracking a broad market index. It invests in a mix of drug makers, medical device companies, and health care service providers. Well-known holdings include Eli Lilly and AbbVie, along with other biotech and medical technology firms. Someone might invest in MEDI to seek long-term growth from medical innovation and the steady demand for health care as populations age. However, this ETF is heavily concentrated in health care stocks, so its price can swing with changes in drug approvals, regulations, and sentiment toward the sector.
How much will it cost me?The Harbor Health Care ETF (MEDI) has an expense ratio of 0.8%, meaning you’ll pay $8 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care companies rather than tracking a broad index.
What would affect this ETF?The Harbor Health Care ETF (MEDI) could benefit from increasing global demand for health care services driven by aging populations, technological advancements, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact funding for health care initiatives or the profitability of its top holdings like Eli Lilly and AbbVie. Its global exposure also makes it sensitive to international health policies and economic conditions.
MEDI Top 10 Holdings
MEDI is very much a health‑care pure play, with Eli Lilly in the driver’s seat and its steady rise giving the fund a solid backbone. Ascendis Pharma and Vaxcyte add a high‑octane biotech flavor, recently climbing but bringing more volatility to the mix. On the flip side, AbbVie and Legend Biotech have been losing steam, acting as mild brakes on performance. Names like UnitedHealth and Danaher provide a steadier, more diversified health‑care presence, but overall this is a globally focused, innovation‑tilted portfolio that leans heavily on a few big medical stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 19.77% | $5.16M | $981.09B | 23.18% | 72 Outperform | |
| Ascendis Pharma | 15.12% | $3.95M | $13.28B | 50.14% | 46 Neutral | |
| AbbVie | 7.70% | $2.01M | $409.15B | 20.03% | 66 Neutral | |
| Vaxcyte | 4.26% | $1.11M | $7.68B | -35.60% | 50 Neutral | |
| Intuitive Surgical | 4.10% | $1.07M | $172.54B | -18.42% | 78 Outperform | |
| Legend Biotech | 3.26% | $850.64K | $3.25B | -51.73% | 46 Neutral | |
| Abivax SA Sponsored ADR | 2.96% | $772.94K | $9.96B | 1589.05% | 60 Neutral | |
| UnitedHealth | 2.94% | $768.45K | $265.58B | -44.00% | 72 Outperform | |
| Natera | 2.87% | $749.03K | $28.53B | 18.94% | 73 Outperform | |
| Rhythm Pharmaceuticals | 2.84% | $741.51K | $6.54B | 72.99% | 59 Neutral |
MEDI Technical Analysis
Negative
―
Price Trends
31.49
Negative
30.80
Negative
28.65
Positive
Market Momentum
-0.27
Positive
41.90
Neutral
31.57
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 31.37, equal to the 50-day MA of 31.49, and equal to the 200-day MA of 28.65, indicating a neutral trend. The MACD of -0.27 indicates Positive momentum. The RSI at 41.90 is Neutral, neither overbought nor oversold. The STOCH value of 31.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDI.
MEDI Peer Comparison
Comparison Results
Performance Comparison
MEDI
Harbor Health Care ETF
30.69
3.45
12.67%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents